The membrane filtration method is the internationally preferred technique for sterility testing of medical devices, verifying the absence of viable microorganisms in accordance with ISO 11737-2 and harmonized pharmacopoeial standards such as USP <71> and Ph. Eur. 2.6.1. By passing device extracts through 0.45 μm membranes, rinsing away inhibitory residues, and incubating the membranes in nutrient media, the method concentrates low-level contaminants while preventing false negatives caused by antimicrobial carryover. This article outlines the principle, applicable sample types, test procedure, method suitability validation, and typical applications of membrane filtration sterility testing for medical devices.
Technical Overview
Sterility testing is the definitive microbiological verification that a medical device is free from viable microorganisms, and it is a core requirement in the definition, validation, and routine control of sterilization processes. For medical devices, the test of sterility is governed by ISO 11737-2 (Sterilization of health care products — Microbiological methods — Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process), which is adopted in Europe as EN ISO 11737-2 and in China as GB/T 19973.2. For combination products and fluid-filled devices, the harmonized pharmacopoeial methods — USP <71>, Ph. Eur. 2.6.1, and the Chinese Pharmacopoeia sterility test — are also widely applied by accredited third-party laboratories and in-house QC facilities.
The membrane filtration method operates on a simple principle: the test fluid, either the product itself or a rinse extract obtained from the device, is drawn through a sterile membrane filter with a nominal pore size of 0.45 μm. Microorganisms suspended in the fluid are retained on the membrane surface. The membrane is then washed with sterile rinse fluid to flush away any bacteriostatic or fungistatic substances, such as preservatives, disinfectant residues, or antimicrobial coatings, that could otherwise suppress the growth of trapped organisms and cause a false negative result. The membrane is subsequently transferred aseptically into culture medium — or medium is introduced directly into a closed filtration canister — and incubated for not fewer than 14 days.
Compared with direct inoculation, the membrane filtration method offers significant advantages for medical devices: it accommodates large rinse volumes from devices with long fluid pathways, concentrates sparse contamination from dilute extracts onto a single recoverable surface, removes inhibitory residues through validated rinsing, and integrates naturally with closed disposable filtration systems that dramatically reduce the risk of laboratory-induced false positives. For these reasons, it is the method of first choice whenever the product characteristics permit filtration.
Testing Samples
The membrane filtration method is applicable to a broad range of medical device categories. The sample preparation strategy depends on the physical form and construction of the device.
Devices with Fluid Pathways
Intravenous infusion sets, blood transfusion sets, hypodermic syringes, needles, single- and multi-lumen catheters, extension tubes, stopcocks, hemodialyzers, and blood oxygenators are tested by perfusing a measured volume of sterile rinse fluid (commonly 0.1% peptone water, known as Fluid A) through the lumen or fluid circuit. The perfusate, which carries any microorganisms present in the fluid path, is then filtered through the membrane.
Solid and Immersible Devices
Implants, sutures, staples, surgical meshes, drapes, gowns, gloves, wound dressings, and absorbable materials are tested by immersing the intact device in a defined volume of rinse medium and agitating, massaging, or vortexing to elute microorganisms from the product surfaces. The resulting extract is filtered. Alternatively, the device may be disassembled and each fluid-contacting component extracted separately when justified by the product construction.
Liquid Products and Aqueous Solutions
Irrigation solutions, dialysis fluids, contact lens care solutions, device lubricants, and other sterile liquids associated with device use are filtered directly through the membrane without an extraction step, provided the volume does not exceed the membrane capacity or is divided across multiple membranes.
Devices with Antimicrobial or Sterilant Residues
Devices sterilized with ethylene oxide, treated with preservatives, or bearing antimicrobial coatings may carry inhibitory residues into the test system. These products require rinse fluids supplemented with validated neutralizers — for example Fluid D containing polysorbate 80 and lecithin — and an increased number of membrane rinse cycles, the effectiveness of which must be demonstrated in the method suitability test.
Testing Items
A complete membrane filtration sterility test program typically comprises the following elements, each of which may be reported as a distinct test item:
- Sterility test by membrane filtration — detection of aerobic bacteria, anaerobic bacteria, and fungi on or in the device, with incubation in two media types over 14 days.
- Method suitability testing (bacteriostasis and fungistasis test) — demonstration that the test method can recover low levels of challenge organisms in the presence of the product.
- Culture media quality control — growth promotion testing of each lot of fluid thioglycollate medium (FTM) and soybean-casein digest medium (SCDM/TSB), plus media sterility checks.
- Positive and negative controls — viability controls with reference organisms and environmental/broth controls to verify aseptic test conditions.
- Confirmation and identification of recovered microorganisms — subculture, Gram staining, and identification to species level (e.g., by MALDI-TOF or sequencing) whenever growth is observed.
- Retest and investigation support — microbiological data packages supporting deviation investigations and batch disposition decisions.
Testing Methods
Test Environment and Aseptic Technique
All manipulations are performed under ISO 14644-1 Class 5 (Grade A) unidirectional airflow, provided within a Class 7 (Grade B) cleanroom background or within a physically sealed isolator. Environmental monitoring of viable and non-viable particles, validated disinfection procedures, gowning controls, and negative controls run in parallel with each test batch provide assurance that any observed growth originates from the product rather than the laboratory environment.
Sample Preparation and Extraction
The device is handled with sterile forceps and gloves. Fluid-path devices are perfused with a documented volume of rinse fluid; solid devices are immersed at a defined ratio of fluid volume to device surface area or mass. Extraction parameters — volume, contact time, and agitation method — are fixed in the test protocol so that the method is reproducible and consistent with the validated method suitability study.
Filtration and Rinsing
The extract is passed through a sterile membrane of 0.45 μm nominal pore size (typically 47 mm diameter) housed in an open stainless-steel filtration assembly or, increasingly, in a pre-sterilized closed canister system. Where required by the B/F validation, the membrane is rinsed with one or more portions of sterile rinse fluid — commonly a minimum of three successive 100 mL rinses — using a neutralizing rinse fluid for inhibitory products. A separate membrane is prepared for each culture medium: one membrane is placed into FTM and one into SCDM.
Incubation and Observation
The inoculated media are incubated for not fewer than 14 days: FTM at 30 °C to 35 °C to favor anaerobic and facultative bacteria, and SCDM at 20 °C to 25 °C to favor aerobic bacteria and fungi. The media are examined visually for turbidity or colonial growth at defined intervals, typically on days 3, 7, and 14 (or daily where an enhanced observation regime is applied). Any evidence of growth is recorded with photographs and retained for confirmation.
Interpretation and Confirmation of Results
If no microbial growth is observed in either medium at the end of incubation, the product complies with the test for sterility. If growth is observed, the suspect medium is subcultured onto appropriate agar, the organism is Gram stained and identified, and the result is evaluated in the context of an investigation to distinguish genuine product contamination from laboratory error. A retest is permitted only under strictly defined conditions — for example, when documented evidence demonstrates that the growth is attributable to faulty materials or technique in the laboratory, or when the identified organism is of unequivocal laboratory or environmental origin and the intrinsic antimicrobial properties of the product have been excluded by the B/F study.
Method Suitability (Bacteriostasis and Fungistasis) Validation
Before a sterility test can be used for release or process validation purposes, the method must be shown capable of detecting low numbers of microorganisms in the presence of the product. Each membrane is inoculated with less than 100 CFU of the following reference strains, processed through the complete test procedure, and compared with positive controls:
- Staphylococcus aureus (e.g., ATCC 6538)
- Pseudomonas aeruginosa (e.g., ATCC 9027)
- Bacillus subtilis (e.g., ATCC 6633)
- Clostridium sporogenes (e.g., ATCC 19404)
- Candida albicans (e.g., ATCC 10231)
- Aspergillus brasiliensis (e.g., ATCC 16404)
Recovery must be comparable to that of the control (commonly accepted as not less than 50 % of the control recovery), demonstrating that no residual inhibitory effect remains after rinsing. The B/F study must be repeated whenever the product formulation, materials, manufacturing process, or test method changes in a way that could affect microbial recovery.
Applications
Membrane filtration sterility testing supports multiple quality and regulatory objectives across the medical device product lifecycle:
- Routine lot release of terminally sterilized devices — confirming process effectiveness for product released against sterilization validation performed to ISO 11137 (radiation), ISO 11135 (ethylene oxide), or ISO 17665 (moist heat).
- Sterilization process validation — including verification dose experiments under ISO 11137-2 dose substantiation methods such as VDmax25, in which a defined number (typically 100) of product units are exposed to the verification dose and individually tested for sterility by membrane filtration.
- Regulatory submissions — microbiological test reports are routinely included in registration dossiers submitted to authorities such as NMPA, and in technical documentation supporting market approval under the EU MDR and other national frameworks.
- Aseptically processed devices — periodic verification of aseptic assembly operations where terminal sterilization is not applicable.
- Shelf-life and stability programs — confirming that product sterility is maintained through the claimed expiry date under real-time and accelerated aging conditions.
- Failure investigations and CAPA — providing confirmatory microbiological evidence during investigations of sterilization deviations, environmental excursions, or customer complaints.
FAQ
Why is membrane filtration preferred over direct inoculation for medical devices?
Membrane filtration handles the large rinse volumes generated by devices with fluid pathways, concentrates low-level contamination from dilute extracts, and removes inhibitory residues that would otherwise suppress growth in direct inoculation. It also pairs well with closed canister systems, which substantially reduce the incidence of laboratory false positives.
What pore size must the membrane have?
A nominal pore size of 0.45 μm is specified by the pharmacopoeial and ISO methods because it reliably retains bacteria and fungi while maintaining acceptable flow rates for the volumes typically filtered during device testing.
Which culture media and incubation conditions are used?
Fluid thioglycollate medium incubated at 30 °C to 35 °C targets anaerobic and facultative organisms, while soybean-casein digest medium incubated at 20 °C to 25 °C targets aerobic bacteria and fungi. Both media are incubated for not fewer than 14 days with periodic visual examination.
Is the bacteriostasis and fungistasis test mandatory?
Yes. Every product-specific sterility test method must be supported by a valid method suitability (B/F) study demonstrating that all six challenge organisms can be recovered through the complete procedure. The study must be refreshed whenever the product, materials, or test conditions change.
What happens if microbial growth is detected?
The organism is confirmed by subculture, Gram stain, and identification. A formal investigation determines whether the growth reflects true product contamination or laboratory error. Retesting is only permitted under narrowly defined criteria; otherwise, the batch is considered to fail the test for sterility.
How long does the overall testing process take?
The standard test requires approximately three weeks including sample preparation, filtration, and the 14-day incubation period. If a method suitability study must be performed or a positive result investigated, additional time is required for organism recovery, identification, and documentation.
How many samples should be tested?
The sample quantity is defined by the sampling plan of the applicable standard — for example, the number of units required for verification dose testing under ISO 11137-2 or the validated release sampling plan of the sterilization process — and must be statistically justified and documented in the test protocol.
